Ken Garfinkel

As Forecasting Director at Lumanity, Ken builds interactive forecast models for early development, prelaunch, and postlaunch healthcare products, including drugs, devices, and diagnostics. The forecasts are customized to meet the particular needs of marketing, marketing research, new product planning, business development, finance, production planning, and senior management. Examples include:
• International long-range plans (LRPs) involving country-level forecast modeling, which are tied to area and international roll ups for financial and production planning
• Epidemiology-based forecasts for products in development, which integrates primary market research, syndicated data, and desk research
• Portfolio forecasting and P&L development, which may be patient or prescription based and usually includes pricing scenarios and dollars
• Evaluation of current forecasting models and stress test assumptions

Ken has over 30 years of forecasting experience in both the biopharmaceutical and consumer products industries. He joined Cello Health Advantage (now Lumanity) in 2013, following independently consulting on short and long-term projects for 11 mid-size and large pharmaceutical companies.

Ken started his career on the corporate side, where he held the following positions:
• Pfizer (previously American Cyanamid): Senior Manager, Forecasting and Statistical Modeling
• Futurion Associates: implemented the Futurcast forecasting system at numerous pharmaceutical and consumer products companies. Conducted seminars on time series forecasting methods
• Novartis (previously Ciba-Geigy): Marketing Scientist (quantitative expert within Market Research)

Ken holds a BA in Mathematics/Statistics and BS in Marketing from the University of Connecticut, and completed 2 years of course work in the PhD program at Stanford University Business School.